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Vascular changes in hemodialysis patients in response to recombinant
human erythropoietin. The partial correction of anemia with recombi-
nant human erythropoietin (rHuEpo) is frequently associated with an
increase in arterial pressure and could oppose the beneficial effect of
anemia correction on myocardial function. In order to analyze the
influence of rHuEpo therapy on the vessels and the heart, we performed
systemic and regional hemodynamics studies in 11 hemodialysis pa-
tients before and 10 to 35 weeks after initiation of rHuEpo therapy,
when hemoglobin concentration was 6.8 0.9 and 10.6 0.66 g/dl
(mean so), respectively. The mean arterial pressure remained un-
changed during this period (88 21 vs. 88 15 mm Hg). Echocardio-
graphic study showed that rHuEpo treatment led to a decrease in left
ventricular end-diastolic diameter (4.9 0.5 vs. 5.1 0.6 cm; P <
0.03), left atrial diameter (3.22 0.30 vs. 3.43 0.33; P <0.03), and left
ventricular mass index (109.8 30.6 vs. 133 30.8 g/m2; P < 0.05).
Left ventricular ejection volume decreased from 86 24 to 75 19 ml
(P < 0.03) and heart rate from 76 9 to 70 10 beats/mm (P < 0.05).
Cardiac index decreased from 4715 700 to 3635 444 mI/minim2 (P
<0.01) and peripheral resistances rose from 1480 162 to 1943 250
dynes sec cm5 m2 (P < 0.01). Fractional ejection and mean
circumferential fiber shortening remained unchanged. The treatment
with rHuEpo did not change the aortic diameters. Aortic distensibility
(pulse wave velocity, PWV) decreased (aortic PWV rose from 804
262 to 907 252 cm/see) but not significantly (P = 0.08). Forearm and
calf blood flow decreased during rHuEpo treatment (4.6 1.4 vs. 6.3
land 3.2 1.2 vs. 4.4 1.6 ml/mn/lOO ml; P <0.01) while the forearm
and calf arterial resistances increased (P < 0.01). Correction of anemia
with rHuEpo induced a significant decrease in forearm and calf venous
distensibility. In the lower limb, we observed a significant increase in
venous tone (with a slope of pressure-volume relationship increasing
from 21 11 to 26 14mm Hg/ml/100 ml (P <0.01), and in the forearm
a significant increase in minimal occluding pressure from 3.4 2.10 to
5.7 3.7 mm Hg (P < 0.01). Our data indicate that correction of renal
anemia with rHuEpo can normalize the heart function and induce
modifications of arteriolar and venous circulations.
Many factors are involved in the anemia of end-stage renal
failure, including hemolysis, marrow toxicity as well as iron and
vitamin deficiency states. However, insufficient secretion of
erythropoietin (Epo) clearly constitutes its major cause [1].
Recombinant Epo (rHuEpo) has become recently available
for patient treatment, and numerous clinical trials performed
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during the last years have fully confirmed the expectation that
intermittent exogenous administration of the hormone is capa-
ble of rapidly improving the hemoglobin levels of hemodialysis
patients [2—6]. Anemia may adversely affect cardiac function in
patients with chronic renal failure, and we have shown that left
ventricular dilatation, a predominant finding in hemodialysis
patients, is closely related to the extent of anemia 171. Correc-
tion of anemia with rHuEpo could therefore improve the
cardiac function. However, with the correction of this type of
anemia by rHuEpo an upward trend of systolic and diastolic
blood pressure has been observed in many patients. In some of
them, it has been necessary to introduce or increase antihyper-
tensive therapy [1, 5,6]. This "hypertensive" effect of rHuEpo
could have a deleterious effect on heart function, and eventually
oppose the beneficial effects of the improvement of anemia.
Different mechanisms may underly such a rise in blood pres-
sure, including an increase of physical activity (secondary to
the correction of the patients' asthenia), an increase of total
blood cell volume, an inadequate or delayed adaptation of
cardiac output (which is normally expected to decrease during
the correction of anemia), an increase in blood viscosity, and an
insufficient adaptation of total peripheral vascular resistance
due to vascular abnormalities in many hemodialysis patients.
The present study had two purposes. The first was to analyze
the effects of therapy with rHuEpo on myocardial function. The
second was to analyze the changes this therapy induced on the
function of large arteries, arterioles, and veins.
Methods
Patients
Eleven uremic patients volunteered to participate in the
study. They were two males and nine females and had a median
age of 29 years (range 17 to 49 years). They were undergoing
intermittent hemodialysis treatment 4 to 4.5 hours thrice
weekly, for a mean period of 7.5 years (range, 1 to 18 years).
The selection criterion for entering study was the need for
regular blood transfusions (12 RBC units during the preceding
12 months or 3 RBC units during the last 4 months) and the
absence of cardiovascular complications included uncontrolled
hypertension. Three patients were treated with antihyperten-
sive drugs (two received Atenolol 50 mg/day and one Captopril
50 mg/day). All patients had evidence of iron overload before
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rHuEpo treatment. None had a cause of anemia other than that
related to their state of chronic renal failure and the treatment
by long-term hemodialysis. Folic acid deficiency was corrected
before and during rHuEpo treatment.
None of the patients had clinically relevant aluminum intox-
ication, severe secondary hyperparathyroidism, a history of
vascular or cardiac disease or diabetes. Five patients were
anephric. All young female patients were submitted to contra-
ceptive methods. All patients gave informed consent to partic-
ipate in the study.
Study protocol
Treatment with rHuEpo was aimed at increasing the patients'
hemoglobin to a stable level comprised between 10 and 12 g/dI.
Intravenous injections of 100 IU rHuEpo kg/body wt were
initiated immediately after the last blood transfusion was given.
Hemodynamic parameters were measured before rHuEpo
administration and repeated 10 to 35 weeks (mean, 23 weeks)
after start of treatment. The initial exploration was done at
distance of a preceding blood transfusion, that is, 4 to 12 weeks
thereafter at a time when blood hemoglobin was 7.5 g/dl (mean,
6.8 g/dl). The second exploration was performed when the
hemoglobin had reached or exceeded a value of 10 gldl (mean,
10.6 g/dl).
Hemodynamic study
We studied cardiac function and systemic hemodynamics
using echocardiography. The study of local flows and arteriolar
resistances was made using plethysmography of the limbs.
Large arteries distensibility was measured by the determination
of the aortic pulse wave velocity (PWV) and aortic diameter.
Finally, the venous distensibility was measured using plethys-
mographic determination of the pressure-volume relationship in
the limbs.
Echocardiographic studies. Two dimensional echography
was performed using Roche Kontron R.T. 400 apparatus.
M-mode echography was done with an IRREX ultrasonograph
using a 2.25 MHz transducer and a Cardio 80 Hewlett Packard
computer (Elkart, Indiana, USA). Echocardiograms were ob-
tained with the patients in semi-recumbent and left lateral
positions from an echocardiographic window located in the
third or fourth intercostal space at the left sternal border.
Echocardiographic data were analyzed following the recom-
mendations of the American Society of Echocardiography [8].
Basic echocardiographic measurements included left ventricu-
lar end-diastolic (LVEDiD) and end-systolic diameters, inter-
ventricular septal thickness (IVST) and left ventricular posterior
wall thickness (LVPWT). All echocardiographic measurements
were calculated on 10 to 15 high quality cycles. Ventricular
volumes, stroke volume and ejection fraction were calculated
from a regression equation described by Teicholz et al [9].
M-mode echographic aortic-valve motion was used to assess
the left ventricular ejection time. The mean velocity of circum-
ferential fiber shortening was calculated using the method of
Cooper et al [10]. The left ventricular mass (LVM) was calcu-
lated according to Devereux and Reichek [11] as:
LVM (g) = 1.04 [(LVEDiD
+ IVST + LVPWT)3 - (LVED1D)31
The same observer performed all echocardiographic measure-
ments. Cardiac output (CO) was estimated as being the product
of stroke volume and heart rate. Total peripheral resistances
(TPR) were calculated according to formula: TPR = (MAP/CO)
x 80, where MAP (mean arterial pressure) = DAP + (SAP-
DAP/3); DAP = diastolic arterial pressure, and SAP = systolic
arterial pressure.
Forearm and leg hemodynamic determinations. Upper and
lower limb blood flow, vascular resistance, and venous disten-
sibility were estimated in supine position by venous occlusion
plethysmography using a mercury strain gauge plethysmo-
graph.
The forearm without AV fistula was placed in 90° adduction,
5 to 10 cm above the heart level (horizontal plane passing
through the reference line for zero). A pneumatic cuff was
placed around the upper arm for venous occlusion. The cuff was
connected to an air reservoir and a mercury manometer for
measurement of cuff pressure during inflation. The gauge was
applied on the arm, 6 cm distal to the lateral epicondyle of the
humerus and calibrated. The venous distensibility was deter-
mined by the method of Wood and Eckstein [12]. The cuff
pressure was increased by small steps of 2 to 3 mm Hg until the
volume started to increase. The pressure just below that value
was considered as the zero level of effective venous pressure
(minimal occluding pressure, MOP). The cuff pressure was then
increased consecutively to 5, 10, 15, 20, 25 and 30 mm Hg. At
each increase, pressure was kept constant until the arm and leg
volume reached maximum value. The plateau was then re-
corded. The same technique was applied in the deflation phase
during which the cuff pressures were decreased by identical
steps from 30 mm Hg to 0 mm Hg. The pressure-volume
relationship showed a typical hysteresis (Fig. 1) and was
analyzed to define simple quantitative parameters of venous
distensibility [13]. The first was the "Venous tone," expressed
as the slope of the linear part of volume pressure relationship
(from 10 to 30 mm Hg of cuff pressure) during the inflation
phase [13]. The slope of this correlation is expressed in mm
Hg/mlIlOO ml. It represents the distensibility of the veins
(APV/V), where zP and i.V = change in pressure and volume,
V = volume. The second was the minimal occluding pressure
(MOP). The MOP could be expressed as the value of the zero
effective venous pressure, or by extrapolation from the linear
part of the volume-pressure relationship as the intercept of
regression line with pressure axis [13]. This latter method was
chosen since its intra-individual reproducibility is better (14
3% for zero effective pressure vs. 7.8 1.7% for extrapolated
MOP). Practically, higher is the "Venous tone" and/or the
MOP, lesser is the venous distensibility.
Determination of aortic pulse-wave velocity. Arterial disten-
sibility is directly related to regional pulse wave velocity
(PWV). According to Moens-Korteweg equation [14]:
PWV (Eh/D'2
where E = elastic modulus; h = wall thickness; D = arterial
diameter; ö = blood density. Therefore PWV could be easily
determined by transcutaneous Doppler flow recordings [14].
Two Doppler flow recordings were taken simultaneously at
the base of the neck in the common carotid artery and right






femoral artery in the groin. Flow was measured with a nondi-
rectional Doppler unit (SEGA M842 10 MHz) with hand held
probes. Transcutaneous Doppler flow waves were recorded on
a Gould tape recorder (M8188) at high speed (100 or 200
mmlsec). PWV was determined as foot-to-foot wave velocity
[14]. The foot of the flow wave was identified as the point of the
commencement of the sharp systolic upstroke. When this could
not be defined precisely, a tangent was drawn to the last part of
the preceding flow wave and to the upstroke of the next wave,
and the foot wave was taken as the point of intersection of these
two lines [14]. The time delay was measured between the feet of
the flow waves recorded in the different points. This was
averaged over at least ten beats and designated as pulse transit
time (t). The distance travelled by the pulse was measured over
the surface of the body with a tape measure as the distance
between the different recording sites (D). Arterial PWV was
determined over the arterial segments as PWV = D/t [14]. For
the measurements of PWV between the base of the neck and
femoral artery, the distance from the suprasternal notch to the
carotid location was subtracted from the total distance to
account for the pulse travelling in the opposite direction and the
PWV was designated as aortic PWV.
Aortic diameters determination. The diameter of the root of
the aorta was measured just above the semilunar valves with a
two-dimensional echocardiograph (Kontron RC 400) and M-
mode echocardiograph (Irrex) using a 2.25 MHz transducer.
The diameter of the abdominal aorta was measured just above
the aortic bifurcation. The aortic internal dimension was eval-
uated with a CGR Sonel 300 echocardiograph, with a 3 to 7.5
MHz transducer. Both longitudinal and transverse scans were
used and the internal diameters of the abdominal aorta were
expressed as the average value.
Values are expressed as mean SD. Wilkoxon's test for
paired data was used. Values of P < 0.05 were considered as
significant.




Height cm 156 10 156 10
Weight kg 46.0 9.8 47.2 10.0 <0.04
BSA m2 1.40 0.18 1.42 0.18 <0.04
SAP mm Hg 124.4 20.8 123.4 20.0
DAP mm Hg 70.3 19.7 72.2 15.9
MAP mm Hg 87.2 20.9 88.2 15.4
Values are mean SD. Abbreviations are: BSA, body surface area;
SAP, systolic arterial pressure; DAP, diastolic arterial pressure; MAP,
mean arterial pressure.
Results
Data concerning the clinical and hemodynamic changes ob-
served during the treatment with rHuEpo are summarized in
Tables 1 through 3. Hemoglobin and hematocrit values in-
creased in all subjects. During the treatment, the patients'
weight increased significantly, inducing an increase in body
surface area (BSA). Arterial blood pressure remained un-
changed. Antihypertensive therapy was given prior to the study
to three subjects in whom no therapeutic adjustment was
necessary. Hemodynamic changes were not different in patients
taking antihypertensive drugs.
The correction of anemia induced a significant decrease in left
atrial dimension (P < 0.03) and in left ventricular end-diastolic
diameter (P < 0.03; Table 2). Left ventricular mass index
decreased significantly from 133 30.8 to 109.8 30.6 g/m2 (P
<0.05). Correction of anemia induced a significant decrease in
left ventricular ejection volume (P < 0.03) and a significant
decrease in heart rate (P < 0.03). Cardiac index was high in
uremic patients (normal values of the laboratory for age and sex
matched controls 3371 173 mI/min/m2), and correction of
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Fig. 1. Forearm and calf volume changes are
shown as a function of pressure changes
during inflation and deflation of the
pneumatic cuff placed around limbs. Studies
were first performed before rHuEpo treatment
and then repeated after the correction of
anemia. Symbols are: control (— — ...O... —
rHuEpo ( • ); inflation (7); deflation(/).
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P
Controls rHuEPO value
LAD cm 3.43 0.33 3.22 0.30 <0.03
LVEDID cm 5.12 0.62 4.86 0.50 <0.03
LVESyD cm 3.16 0.46 3.08 0.33
PWTh cm 0.87 0.14 0.82 0.17
IVSTh cm 0.89 0.15 0.87 0.12
LVMi g/rn2 133.0 30.8 109.8 30.6 <0.05
% Shortening 38.1 5.0 37.0 2.0
Ejection fraction % 68.4 6.1 67.2 3.1
Ejection volume ml 86.3 24.0 75.2 18.9 <0.03






LVET rn/sec 302 28 309 24
Vcf circle/sec 1.28 0.26 1.21 0.15
Values are mean SD. Abbreviations are: LAD, left atrial diameter;
LVEDiD, left ventricular end-diastolic diameter; LVESyD, left ven-
tricular end-systolic diameter; PWTh, posterior wall thickness; IVSTh,
interventricular septal thickness; LVMi, left ventricular mass index;
LVET, left ventricular ejection time; Vcf, mean circumferential fiber
shortening; TPR, total peripheral resistance.
0.01) and an increase in systemic peripheral resistances (P <
0.01; Table 2). Aortic PWV increased but not significantly (P =
0.08). Forearm and calf blood flow were increased in dialysis
patients (normal values of the laboratory for age and sex
matched controls: 3.0 0.7 ml/min/100 ml for calf blood flow
and 3.5 1.2 ml/min/100 for forearm blood flow). The correc-
tion of anemia induced a significant decrease in forearm and calf
blood flows (P < 0.01), with a significant (P < 0.02) increase in
limb vascular resistances (Table 3). Treatment with rHuEpo
induced a significant decrease in venous distensibility with an
increase in calf venous tone and an increase in forearm MOP.
Changes in venous tone of upper and lower limbs during cuff
inflation and deflation averaged for all patients are depicted in
Figure 1. The latter results indicate that the correction of
anemia induced a "venoconstriction" characterized by a reset
towards higher pressures of the pressure volume curves.
Discussion
The results of the present study indicate that the main
hemodynamic changes observed during the correction of ane-
mia with rHuEpo in dialysis patients are: 1) a reduction of the
size of the left heart cavities and a decrease of the left
ventricular mass index; 2) a decrease in the systemic and
regional blood flows; 3) a venoconstriction of the limbs; and 4)
an absence of significant changes in aortic distensibility and
diameters.
An enlargement of the left ventricular cavities is frequently
observed in hemodialysis patients [7, 15]. The most obvious
reason for the left ventricular dilation is chronic flow overload.
In the absence of overt fluid overload, the role of the dialysis
fistula and anemia seem determinant and it has been shown that
severe anemia, per se, can result in cardiac dilation in both
nonuremic [161 and uremic subjects [71.
The results of the present study confirm the relationship
4175 700 3635 444 <0.01
1480 162 1943 250 <0.01
Aortic diameter cm sigmoid valves 2.63 0.30 2.63 0,33
Aortic diameter cm abdominal 1.40 0.20 1.32 0.20
Aortic PWV cm/sec 804 262 907 252
Forearm BF m!/100 mi/mm 6.3 1.0 4.6 1.4
Forearm YR Units 14.2 4.2 21.2 7.0
Calf BF m!I100 mi/mm 4.4 1.6 3.2 1.2
Calf YR U 22.7 9.9 31.1 13.0
Forearm VT mm Hg/m!/IOO ml 23.8 7.5 23.7 5.8
Calf VT mm Hg/mlilOO ml 20.9 11.3 25.7 13.7
Forearm MOP mm Hg 3.4 2.1 5.7 3.7
Calf MOP mm Hg 8.3 4.6 7.7 4.5
between left ventricular dimensions and anemia and are in
agreement with clinical observations which evidenced a de-
crease of chest X-ray heart size in patients after their anemia
had been corrected with rHuEpo for several months [1]. An
increase in left atrial dimension is also frequently observed in
dialysis patients and is interpreted as resulting from a decreased
compliance of the left ventricle and impaired ventricular filling
[17]. The present results show that correction of anemia can
also decrease left atrial size. Therefore, chronic flow overload
appears to contribute to the generalized dilation of the heart
cavities. The reduction of left ventricular diameter in the
absence of any changes in arterial pressure induces a decrease
in left ventricular stress [181 and could be responsible for the
observed reduction in LVM. The decrease in left ventricular
dimension is accompanied by a reduction of left ventricular
ejection volume and a decrease in heart rate. These changes
result in a decrease in cardiac output and an increase in total
peripheral resistances, as previously demonstrated by Kim et al
after blood transfusions [19]. Such a decrease in cardiac dimen-
sions and cardiac output under rHuEpo treatment has also very
recently been observed by Low et al [20] using echocardio-
graphic methods. In contrast, Verbeelen et al [21] report an
increase in cardiac output, based on radionuclide method,
together with a decrease in total peripheral resistance, after
rHuEpo administration in dialysis patients. The apparent dis-
crepancy of findings could be due to a shorter observation
period in the latter patients group, to a different clinical status of
the patients included in the study, and/or to methodological
differences in the evaluation of cardiac function parameters.
In parallel with the above systemic changes, the present
study shows that correction of anemia induces a significant
decrease in regional blood flows, as demonstrated by the
significant reduction in limb musculo-cutaneous blood flows
(Table 3) and an increase in regional vascular resistance. The
changes in vascular resistances during the treatment with
rHuEpo can result from the increase in whole blood viscosity,
from a better tissue oxygenation with suppression of hypoxic
vasodilation, or possibly from a direct vascular effect of the
hormone. There is no doubt that the rise in hematocrit increases
whole blood viscosity, and according to Poiseuille's law in-
duces a direct variation in vascular resistances. As the resis-
tance to flow is calculated and not determined directly, it is
Table 2. Echocardiographic parameters and the effects of
erythropoietin (rHuEPO) treatment
Table 3. Changes in arterial and venous function during
erythropoietin (rHuEPO) treatment







Values are mean so. Abbreviations are: PWV, pulse wave veloc-
ity; BF, blood flow; VR, vascular resistances; VT, venous tone; MOP,
minimal occluding pressure.
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impossible to determine if the increase in resistances in our
patients is only due to the change in viscosity or if other
determinants, such as vessel geometry or changes in the phys-
ical properties of the vasculature, are involved. A direct eval-
uation of the physical and hemodynamic characteristics of the
different vessels was done in the present study. The results
indicate that changes in hematocrit did not significantly modify
the physical properties of the aortic wall as determined from the
evaluation of aortic distensibility by PWV.
Contrasting with this, present results indicate that correction
of the anemia induced a significant "venoconstriction" af-
fecting the limb veins. During the treatment with rHuEpo,
changes in the venous system were observed both in the
forearm and in the calf. The changes in venous function can
result from passive elastic recoil of the veins subsequent to
modifications of the blood flow and resistances, or from an
active venoconstnction [22]. Indeed, when arterial blood flow
decreases and vascular resistances increase, there is also a
decrease in venous flow, that is, a decrease in the pressure
gradient along the veins and a passive adjustment of the venous
flow which decreases [22]. As the venous distensibility is
pressure-dependent [22], the lower venous pressures which
would result from purely passive adjustment would be accom-
panied by an increase in compliance. This is not what has been
observed in the present study, suggesting that the changes in
venous function were the result of an active adjustment.
The changes in blood viscosity resulting from the increase in
hematocrit occur at all shear rates, but are more pronounced for
low shear rates, corresponding to blood velocity profiles in the
veins [23]. As demonstrated by Guyton and Richardson [24],
blood viscosity is a major determinant of the resistance to
venous return, that is, of the cardiac filling [24]. Therefore, the
"venoconstriction" observed during the correction of anemia
with rHuEpo may be directed to maintain an adequate venous
return and cardiac filling. The nature of this adaptation remains
to be determined.
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